Long Term Investment in Pharma Company – Lupin
Investments with a two-year perspective can be made in the shares of pharma company Lupin, whose sales have grown by 14 per cent and profits by 33 per cent on a compounded annual basis over the last five years. Lupin is one of the few drug makers that has consistently grown both in India and abroad.
Today, for every Rs 10 earned by Lupin and its subsidiaries, international revenues account for Rs 6 while the domestic business chips in with the remaining Rs 4.Formulations or finished dosages have been one of Lupin’s growth drivers in regulated markets such as the US and UK.
Lupin’s core strengths lie in high-value therapeutic areas such as anti-infectives, cephalosporins and pain management; while it diligently invested resources to focus on research and development on niche intellectual property (earned Rs 240 crore as R&D licensing income in 2007-08).
With Lupin now entering Japan, the world’s second largest pharma market, it adds a crucial geography to its basket of advanced markets.
*To get the password for buy calls, please subscribe to this blog. You will receive the password in next email to you*If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
No comments yet.
Leave a comment